BioSpace News Archive

Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system (CNS) diseases, today announced that it has licensed a sixth gene therapy development program under its research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program (GTP).

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the Company has been awarded a dual-source group purchasing agreement by Premier, Inc. to supply implantable infusion ports.

Masimo (NASDAQ: MASI) announced today three additional indices (delta cHb, delta HHb, and delta O2Hb) for O3® Regional Oximetry.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical needs, today announced the appointment of Gunnar Kaufmann, Ph.D., as Chief Scientific Officer and Igor Bilinsky, Ph.D., as Chief Business Officer.

Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers, today announced the appointment of Gary Gordon, M.D., Ph.D., as its Chief Medical Officer.

Below is British American Tobacco response to this statement.

Appoints Joel Smith as General Counsel and Executive Vice President of Corporate Development

Senior leader appointed as agency broadens focus across life sciences industry

In addition to the presentation by Dr. Jonathan C. Javitt, the Company’s CEO, the Company will be available for 1x1 meetings.

Gene therapy product WP-REP1 comprised of DNA nanoparticles to treat the Inherited Retinal Disease Choroideremia